Use of the QuantiFERON®-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 6, 2009, Pages 726-730

  Kunimoto, Dennis ^a,b   Der, E ^a   Beckon, A ^a   Thomas, L ^a   Egedahl, M ^a   Beatch, A ^a   Williams, G ^a   Tyrrell, G ^a   Ahmed, R ^a   Brown, N ^a   Long, R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Cost; Diagnosis; Interferon; Tuberculin; Tuberculosis

Indexed keywords

GOLD; TUBERCULIN;

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DIAGNOSTIC TEST; EMPLOYMENT; EQUIPMENT; FEMALE; HUMAN; IMMIGRATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; AGE; AGED; ANALYTICAL EQUIPMENT; COMPARATIVE STUDY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; REPRODUCIBILITY; RISK FACTOR; STATISTICS;

ADULT; AGE FACTORS; AGED; ALBERTA; AMBULATORY CARE FACILITIES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 67649170934     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204. (Pubitemid 44713473)
2. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
3. Mazurek G H, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: 49-55.
4. British National Institute for Health and Clinical Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: NICE, 2006. http://www.nice.org.uk/guidance/CG33 Accessed August 2008.
5. Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008; 34: 1-13.
6. Dewan P K, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura L M. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006; 6: 47.
7. Hoeppner V, Marciniuk D, Hershfield E. Treatment of tuberculosis disease and infection. In: Long R, ed. Canadian tuberculosis standards. 5th ed. Ottawa, Ontario, Canada: Canadian Lung Association and Government of Canada, 2000: pp 96-98.
8. Menzies D, Oxlade O, Lewis M. Costs for tuberculosis care in Canada. Ottawa, Ontario, Canada: Public Health Agency of Canada, 2006. http://www.phac-aspc.gc.ca/tbpc-latb/costtb/index-e.html Accessed August 2008.
9. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26. (Pubitemid 46101841)
10. Wrighton-Smith P, Zellweger J P. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006; 28: 45-50. (Pubitemid 44914259)
11. Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28: 35-44. (Pubitemid 44914258)
12. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect 2009; 58: 197-204.
13. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354. (Pubitemid 351650594)
14. Choi J C, Shin J W, Kim J Y, Park I W, Choi B W, Lee M K. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest 2008; 133: 1415-1420.
15. von Reyn C F, Horsburgh C R, Olivier K N, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5: 1122-1128. (Pubitemid 34033213)
16. Pouchot J, Grasland A, Collet C, Coste J, Esdaile J M, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997; 126: 210-214.
17. Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009; 13: 84-92.
18. Hill P C, Brookes R H, Fox A, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007; 4: e192. (Pubitemid 46998623)
19. Higuchi K, Harada N, Mori T, Sekiya Y. Use of QuantiFERON-TB Gold to investigate tuberculosis contacts in a high school. Respirology 2007; 12: 88-92.
20. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-1170. (Pubitemid 351717577)